512783-90-3

Upstream product

• 71449-08-6 (2R)-2-{[(benzyloxy)carbonyl]amino}-4-tert-butoxy-4-oxobutanoic acid 
• 2740-83-2 3-(TRIFLUOROMETHYL)BENZYLAMINE 
• 512783-84-5 N-[(benzyloxy)carbonyl]-D-aspartic acid β-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide 

Downstream Products

• 1354566-10-1 C₂₅H₂₇F₃N₂O₃ 
• 512783-99-2 3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-(3-trifluoromethyl-benzyl)-succinamic acid tert-butyl ester 
• 512784-07-5 3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-(3-trifluoromethyl-benzyl)-succinamic acid 
• 1013626-95-3 C₂₅H₂₇F₃N₂O₃ 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY

Compounds, and compositions, methods, and uses thereof, are described herein for treating brain injuries.

BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS

Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.

COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES

Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treati

METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER

Compounds and compositions are described herein for treating post tramatic stress disorder.

BETA-LACTAM CANNABINOID RECEPTOR MODULATORS

Described herein are substituted 2-(azetidin-2-on-l-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CBl) and/or canna

Azetidinones as vasopressin V1a antagonists

The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing h

β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS

β-lactamyl alkanoic acids and pharmaceutical compositions thereof are described. Methods for treating various diseases and disease states using one or more β-lactamyl alkanoic acids are also described. Substituted 2-(azetidin-2-on-l-yl)alkanedioic acids,

HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS

3-Hydroxy and 3-keto substituted 2-(azetidin-2-on-l-yl)alkanedioic acids, and analogs and derivatives thereof are described. Methods for using 3-hydroxy and 3-keto substituted 2-(azetidin-2-on-l-yl)alkanedioic acids, and analogs and derivatives thereof, i

BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS

0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more β-lactamyl alkanoic acids are also described.

3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS

Novel 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof are described. Methods for using 2-(azetidin-2-on-l-yl)alkanedioic acids and derivatives thereof in the treatment of disease states responsive to antagonism of the vasopressin V1a